Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05610865

Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers

Autologous Adipose Tissue Derived Stromal Vascular Fraction Versus Cultured Adipose Derived Stem Cells for the Treatment of Chronic Diabetic Wounds

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
28 (estimated)
Sponsor
University of the Punjab · Academic / Other
Sex
All
Age
20 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.

Detailed description

Under local or general anesthesia, autologous fat will be harvested by using a manual aspiration or syringe-assisted technique. SVF and ASCs isolation from autologous lipoaspirates will be done by enzymatic digestion method (collagenase Type-1 solution for 45 minutes at 37°C). Cell quality assessment will be done prior to transplantation by trypan blue exclusion assay and total populations and fractions of cells identified by immunocytochemistry / flow cytometry. PRP will be derived by centrifugation from 50-100ml blood collected in anticoagulant carrying bag, from patient at the day of transplantation. The injection volume will depend on the wound area of each patient. 2 million cells/ 0.5 ml PRP will be mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

Conditions

Interventions

TypeNameDescription
OTHERControl; Standard-of-care managementPatients will undergo conventional wound care management.
BIOLOGICALOnly PRP injectionOnly PRP injected / cm2 intradermally at the border zone \& inside of wound surface bed.
BIOLOGICALPRP + SVF injectionUncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.
BIOLOGICALPRP + ASCs injectionCultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone \& inside of wound surface bed.

Timeline

Start date
2020-11-20
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2022-11-09
Last updated
2024-12-31

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT05610865. Inclusion in this directory is not an endorsement.